HOPKINTON, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Alseres
Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a
conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the
second quarter ending June 30, 2008 and discuss other matters related to the
Company.
To access the conference call, please dial 877-879-6201 for domestic and
719-325-4816 international. The code for this conference call is 4315502.
Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of
the call will be posted on the Investor Relations section of our website,
www.alseres.com, within 48 hours following the conference call and will be
available through Thursday, August 28th, 2008.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company's
focus is reflected in several important initiatives. Cethrin, a recombinant-
protein-based drug designed to promote nerve repair after acute spinal cord
injury, demonstrated positive interim results in a Phase I/IIa clinical trial.
The Company's research and pre-clinical programs include, Inosine for the
treatment of spinal cord injury and stroke, Oncomodulin for the treatment of
ocular injury and disease and research programs directed at a number of
regenerative therapies including bone repair. The Company has a robust
molecular imaging development program targeting diagnosis of Parkinson's
disease and potentially dementia. The Company's lead molecular imaging product
candidate is Altropane which is in Phase III clinical trials for the diagnosis
of Parkinsonian Syndromes including Parkinson's disease. The Company has
research collaborations with Harvard Medical School and Children's Hospital
Boston.
Forward-Looking Statements
The foregoing release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements include statements regarding Alseres' future expectations,
beliefs, intentions, goals, strategies, plans or prospects regarding the
future, including the development and commercialization of Altropane and
Cethrin, the prospects of the Company's CNS and regenerative therapeutics
programs, the Company's strategies to develop and commercialize axon
regeneration technologies and the breadth of the Company's technologies and
intellectual property portfolio. Forward-looking statements can be identified
by terminology such as "anticipate," "believe," "could," "could increase the
likelihood," "estimate," "expect," "intend," "is planned," "may," "should,"
"will," "will enable," "would be expected," "look forward," "may provide,"
"would" or similar terms, variations of such terms or the negative of those
terms. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks, uncertainties and
factors referred to in the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2008 filed with the Securities and Exchange Commission
under the section "Risk Factors," as well as other documents that may be filed
by Alseres from time to time with the Securities and Exchange Commission. As a
result of such risks, uncertainties and factors, the Company's actual results
may differ materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained herein.
Alseres is providing the information in this press release as of this date and
assumes no obligations to update the information in this press release.
Alseres, Cethrin and Altropane are registered trademarks of Alseres
Pharmaceuticals, Inc.
Contact:
Sharon Correia - 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc.
scorreia@alseres.com
Adam Friedman - 212-981-2529 ext. 18
Adam Friedman Associates
adam@adam-friedman.com
.gif)
